Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas.
J Nucl Med
; 38(5): 682-6, 1997 May.
Article
in En
| MEDLINE
| ID: mdl-9170427
ABSTRACT
UNLABELLED Technetium-99m-MIBI was initially developed for heart studies but it can also be used to depict tumors, predict multidrug resistance and evaluate chemotherapy. Recently, 99mTc-tetrofosmin, which exhibits similar physical properties, has been launched for heart studies. Tumor uptake and prediction of multidrug resistance have also been reported regarding the latter tracer. A comparison of these two tracers regarding the detectability of musculoskeletal sarcoma has been made. METHODS:
Twenty patients with musculoskeletal sarcoma of the extremities or pelvis underwent planar examination after the administration of 99mTc-MIBI and 99mTc-tetrofosmin with an interval of 2-7 days. The tumor activity was compared with one ipsilateral and one contralateral background region.RESULTS:
There was a small, but not significant, difference in favor of 99mTc-MIBI with regard to both background regions.CONCLUSION:
Technetium-99m-MIBI and 99mTc-tetrofosmin can both be used to visualize musculoskeletal sarcomas. The choice may depend on which agent is used routinely for myocardial studies in the laboratory.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organophosphorus Compounds
/
Sarcoma
/
Bone Neoplasms
/
Organotechnetium Compounds
/
Technetium Tc 99m Sestamibi
/
Muscle Neoplasms
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Nucl Med
Year:
1997
Type:
Article
Affiliation country:
Sweden